We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Quest Diagnostics (DGX - Free Report) recently introduced 13 blood tests designed to evaluate micronutrient deficiencies, enabling people to determine if they are lacking certain vitamins and minerals required to maintain optimal health. These panels are now available for consumer purchase exclusively on questhealth.com.
The recent development underscores the company’s dedication to offering accessible, personalized and consumer-driven health insights that can make a meaningful difference in daily lives. Quest Diagnostics has priced these tests between $65 and $299 and is set to launch more tests in the coming weeks.
Relevance of the Tests
Micronutrients are essential vitamins and minerals that are vital for well-being and disease prevention, but deficiencies can commonly be caused by food allergies and dietary restrictions, certain prescription medications or chronic health conditions. At least one in three Americans are at risk of nutrient deficiencies.
Nearly 48.6% of people are observed to have used at least one prescription drug in the past 30 days, while 60% of Americans live with at least one chronic disease. Research has linked both prescription medication and chronic health conditions with potential treatment-induced or disease-state-induced micronutrient deficiencies, respectively.
Image Source: Zacks Investment Research
The COVID-19 pandemic has accelerated the global shift toward greater agency and ownership of personal health. More specifically, these have prompted many consumers to explore factors impacting their overall well-being, and many have become more engaged in managing their health. With the introduction of the new micronutrient panels, questhealth.com strives to help individuals identify and seek answers to nutritional concerns as they continue working toward living a proactive, healthy lifestyle.
More on the News
Quest Diagnostics’ new 13 micronutrient deficiency panels are the first consumer-initiated blood-draw tests specifically designed to cater to those who may have insufficient nutrient intake due to certain health factors. These include dietary restrictions influenced by certain food allergies to milk, soy, eggs, tree nuts and prescription medications (such as oral contraceptives, proton pump inhibitors, diuretics and Corticosteroids) and chronic health conditions (including Celiac disease and thyroid disorders).
Last year, the company launched the Vitamin & Nutrition lab test category with a broad range of diet-specific nutrient deficiency tests, especially targeting consumers who follow vegetarian/vegan, high-protein, high-fat and low-carb diet lifestyles. These tests provide an opportunity to better understand if their diets are meeting their unique nutritional needs.
Industry Prospects
Per a Market Research Future report, the vitamin test market was valued at $0.52 billion in 2023 and is expected to witness a CAGR of 4.3% by 2032. Increasing consumer awareness of the relevance of vitamin testing for overall health and well-being, as well as growing demand for individualized nutrition and health solutions, is a key market driver.
Recent Developments
A recent study by Quest Diagnostics and the University of Alabama found gaps in adherence to guideline-based laboratory testing and treatment of pregnant women for two of the most prevalent sexually transmitted infections (STIs) in the United States. This can potentially have serious consequences on maternal and newborn health.
According to researchers, improved adherence to existing recommendations, harmonization of guidelines across agencies as well as updated recommendations for STI testing are crucial to ensuring that mothers and newborns in the United States receive medically appropriate testing and treatment.
Price Performance
In the past six months, shares of the company have rallied 22.2% compared with the industry’s rise of 12%.
Zacks Rank and Other Key Picks
Quest Diagnostics currently carries a Zacks Rank #2 (Buy).
Masimo shares have risen 12% in the past year. Estimates for the company’s earnings have increased from $3.63 to $3.83 in 2024 and from $3.97 to $4.20 in 2025 in the past 30 days.
MASI’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 14.6%. In the last reported quarter, it posted an earnings surprise of 11.7%.
Estimates for Boston Scientific’s 2024 earnings per share have moved to $2.40 from $2.32 in the past 30 days. Shares of the company have rallied 55.2% in the past year compared with the industry’s rise of 11.2%.
BSX’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 7.2%. In the last reported quarter, it delivered an earnings surprise of 6.9%.
Estimates for Myriad Genetics’ 2024 earnings have moved to 5 cents from 3 cents per share in the past 30 days. Shares of the company have improved 58.8% in the past year against the industry’s 9.1% fall.
MYGN’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 213.4%. In the last reported quarter, it delivered an earnings surprise of a staggering 600%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Quest Diagnostics (DGX) Debuts Micronutrient Deficiency Panels
Quest Diagnostics (DGX - Free Report) recently introduced 13 blood tests designed to evaluate micronutrient deficiencies, enabling people to determine if they are lacking certain vitamins and minerals required to maintain optimal health. These panels are now available for consumer purchase exclusively on questhealth.com.
The recent development underscores the company’s dedication to offering accessible, personalized and consumer-driven health insights that can make a meaningful difference in daily lives. Quest Diagnostics has priced these tests between $65 and $299 and is set to launch more tests in the coming weeks.
Relevance of the Tests
Micronutrients are essential vitamins and minerals that are vital for well-being and disease prevention, but deficiencies can commonly be caused by food allergies and dietary restrictions, certain prescription medications or chronic health conditions. At least one in three Americans are at risk of nutrient deficiencies.
Nearly 48.6% of people are observed to have used at least one prescription drug in the past 30 days, while 60% of Americans live with at least one chronic disease. Research has linked both prescription medication and chronic health conditions with potential treatment-induced or disease-state-induced micronutrient deficiencies, respectively.
Image Source: Zacks Investment Research
The COVID-19 pandemic has accelerated the global shift toward greater agency and ownership of personal health. More specifically, these have prompted many consumers to explore factors impacting their overall well-being, and many have become more engaged in managing their health. With the introduction of the new micronutrient panels, questhealth.com strives to help individuals identify and seek answers to nutritional concerns as they continue working toward living a proactive, healthy lifestyle.
More on the News
Quest Diagnostics’ new 13 micronutrient deficiency panels are the first consumer-initiated blood-draw tests specifically designed to cater to those who may have insufficient nutrient intake due to certain health factors. These include dietary restrictions influenced by certain food allergies to milk, soy, eggs, tree nuts and prescription medications (such as oral contraceptives, proton pump inhibitors, diuretics and Corticosteroids) and chronic health conditions (including Celiac disease and thyroid disorders).
Last year, the company launched the Vitamin & Nutrition lab test category with a broad range of diet-specific nutrient deficiency tests, especially targeting consumers who follow vegetarian/vegan, high-protein, high-fat and low-carb diet lifestyles. These tests provide an opportunity to better understand if their diets are meeting their unique nutritional needs.
Industry Prospects
Per a Market Research Future report, the vitamin test market was valued at $0.52 billion in 2023 and is expected to witness a CAGR of 4.3% by 2032. Increasing consumer awareness of the relevance of vitamin testing for overall health and well-being, as well as growing demand for individualized nutrition and health solutions, is a key market driver.
Recent Developments
A recent study by Quest Diagnostics and the University of Alabama found gaps in adherence to guideline-based laboratory testing and treatment of pregnant women for two of the most prevalent sexually transmitted infections (STIs) in the United States. This can potentially have serious consequences on maternal and newborn health.
According to researchers, improved adherence to existing recommendations, harmonization of guidelines across agencies as well as updated recommendations for STI testing are crucial to ensuring that mothers and newborns in the United States receive medically appropriate testing and treatment.
Price Performance
In the past six months, shares of the company have rallied 22.2% compared with the industry’s rise of 12%.
Zacks Rank and Other Key Picks
Quest Diagnostics currently carries a Zacks Rank #2 (Buy).
Some other top-ranked stocks in the broader medical space are Masimo (MASI - Free Report) , Boston Scientific (BSX - Free Report) and Myriad Genetics (MYGN - Free Report) . While Masimo sports a Zacks Rank #1 (Strong Buy) at present, Boston Scientific and Myriad Genetics each carry a Zacks Rank #2. You can see the complete list of today’s Zacks Rank #1 stocks here.
Masimo shares have risen 12% in the past year. Estimates for the company’s earnings have increased from $3.63 to $3.83 in 2024 and from $3.97 to $4.20 in 2025 in the past 30 days.
MASI’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 14.6%. In the last reported quarter, it posted an earnings surprise of 11.7%.
Estimates for Boston Scientific’s 2024 earnings per share have moved to $2.40 from $2.32 in the past 30 days. Shares of the company have rallied 55.2% in the past year compared with the industry’s rise of 11.2%.
BSX’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 7.2%. In the last reported quarter, it delivered an earnings surprise of 6.9%.
Estimates for Myriad Genetics’ 2024 earnings have moved to 5 cents from 3 cents per share in the past 30 days. Shares of the company have improved 58.8% in the past year against the industry’s 9.1% fall.
MYGN’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 213.4%. In the last reported quarter, it delivered an earnings surprise of a staggering 600%.